Going concern and potential cessation of operations
The company has minimal revenue, recurring losses, and stated that existing funds may not support operations for 12 months.
- Scope
- Enterprise-wide
- Materiality
- high
Aditxt, Inc.
Aditxt, Inc. is a development-stage biotechnology company focused on immune monitoring and other life-science technologies rather than a mature commercial pharmaceutical manufacturer. Its core platform, AditxtScore™, is designed to create a personalized profile of immune responses across viruses, bacteria, drugs, supplements, transplants, and cancer-related agents. The company has also pursued strategic transactions and licensing structures to commercialize its technologies and expand its product footprint. In the latest filings, Aditxt disclosed minimal revenue, significant operating losses, and substantial going-concern uncertainty, indicating that it remains in an early, capital-dependent phase.
−20 337,9 %
−368,3 %
−30 117,9 %
−79,2 %
0.09
0.09
| % | |
|---|---|
| Immune profiling diagnostics | 80% Technology that measures and interprets immune responses to pathogens, drugs, supplements, and other clinical agents. |
| Technology licensing | 15% Licensing and sublicensing arrangements for commercialization of AditxtScore and related intellectual property. |
| Strategic corporate development | 5% Merger, acquisition, and partnership activity intended to expand the company’s platform and market access. |
Aditxt’s direct customers appear to be clinical, research, and commercial partners that can use immune-response data or...
- Diagnostic and clinical partnersprimary
Buy or integrate immune-profiling capabilities for testing and patient monitoring, especially where immune response data has clinical value.
- Technology licenseesprimary
License AditxtScore or related IP to commercialize the platform in their own channels or geographies.
- Research and translational medicine userssecondary
Use the platform for studies of immune response to viruses, drugs, supplements, transplants, and cancer-related agents.
- Strategic transaction partnerssecondary
Merger or acquisition counterparties that may provide assets, scale, or commercialization pathways.
Aditxt is headquartered in Mountain View, California and is incorporated in Delaware, so its operating base is in the...
- •Headquartered in Mountain View, California
- •Incorporated in Delaware, United States
- •No disclosed country-level revenue breakdown in the excerpts
- •Worldwide sublicensing indicates potential non-U.S. commercialization reach
- •Current operations are primarily U.S.-based and development-stage
Aditxt’s strategy is centered on advancing immune-monitoring technology and finding commercialization pathways through...
01
Commercialize AditxtScore through partners and licenseesshort-term
The company lacks meaningful direct sales, so partner-led commercialization is the main route to monetization.
02
Secure financing and manage liquidityshort-term
The company disclosed substantial doubt about going concern and overdue vendor obligations, making capital access essential.
03
Pursue strategic transactions to broaden the platformmedium-term
M&A and merger activity may provide assets, technology, or commercialization channels that the company cannot build alone.
Aditxt faces acute going-concern and liquidity risk because it has generated only minimal revenue while continuing to...
Liquidity pressure from overdue payables and debt
Management disclosed significant vendor obligations past due and the possibility of default if obligations cannot be refinanced or repaid.
- Scope
- Accounts payable and secured/unsecured debt
- Materiality
- high
Weak commercialization of AditxtScore
Revenue declined as orders fell with reduced COVID testing, showing limited and volatile demand.
- Scope
- Product revenue
- Materiality
- high
Failure of strategic transactions
The company incurred costs pursuing mergers and sublicensing arrangements that may not close or may be terminated.
- Scope
- M&A and licensing pipeline
- Materiality
- medium
Revenue recognition for AditxtScore and licensing
Reported revenue and gross margin
Research and development estimates
Operating loss and cash burn
Stock-based compensation
Operating expenses and net loss
Going-concern and liquidity disclosures
Financial statement presentation and risk assessment
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Adicet Bio, Inc.
ACET · Pharmaceutical Preparations
AddLife
ALIF-B.ST · Health Care
AddLife is a European company specializing in the distribution and development of advanced medical technology products and laboratory equipment.
Aptevo Therapeutics Inc.
APVO · Pharmaceutical Preparations
CDT Equity Inc.
CDT · Pharmaceutical Preparations
Insight Molecular Diagnostics Inc.
IMDX · In Vitro & In Vivo Diagnostic Substances
: 11/08/2026